Clinical Trials · NCT04852679

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Name: Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lanreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 43
Start date: May 2021
Locations: 14 sites, China
Primary endpoint: Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24

View Lanreotide compound reference